Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

UBS's Trung Huynh lowered their price target on Eli Lilly & Co (NYSE: LLY) by 4.5% from $1,100 to $1,050 on 2025/05/03. The analyst maintained their Strong Buy rating on the stock.

Eli Lilly & Co. reported its Q1 2025 earnings.

Given the strong performance of the GLP franchise, Huynh argued that the current selloff is excessive.

Earnings Report

For Q1 2025, Eli Lilly & Co reported:

• EPS of $3.34, which missed the Zacks Consensus Estimate of $3.52 but beat, by 29%, Q1 2024’s $2.58.
• Revenue of $12.73B, which beat the Zacks Consensus Estimate by 0.86% and, by 45%, Q1 2024’s $8.77B.

For FY 2025, management guided:

• EPS of $20.78 to $22.28.
• Revenue of $58B and $61B.

Chairman & CEO David A. Ricks commented: "Lilly had a solid start to the year, with 45% Y/Y revenue growth driven by strong sales of Mounjaro and Zepbound.

"Our pipeline continued to deliver across key therapeutic areas, with product approvals in oncology and immunology, and the exciting success of our oral incretin, orforglipron, in the first of seven late-stage studies in diabetes and obesity. 

“To support global demand for our newest medicines, we're accelerating our manufacturing investments, as underscored by our recent announcement to build four new facilities."